Go to industries

Healthcare

Critical guidance on your journey

With new and groundbreaking technology constantly challenging the status quo, the healthcare industry is progressing by leaps and bounds. But in an industry built on regulations, strategic partnerships are often the key to successfully developing businesses. Our passionate advisors, backed by sub-sector teams globally, use their deep expertise in M&A, growth equity and ECM, debt advisory and corporate finance services to find your competitive edge, navigate local customs and help you create the most suitable strategy.

Contact advisor
Worldwide
518
deals closed in Healthcare
Worldwide
Explore all our industry-related deals
Go to deals
Valtronic has sold two operating subsidiaries to Cicor Group
Healthcare

Valtronic has sold two operating subsidiaries to Cicor Group

Cicor Group has acquired the US and Moroccan subsidiaries of Valtronic. Through this transaction, Valtronic’s shareholders have secured the long-term development and success of the two entities, while Cicor gains access to the US market and doubles its production capacity in Morocco.

Learn more
Afric Phar has been acquired by Pharma Capital
Healthcare

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Learn more
Olyos Group has acquired a controlling stake in NewScience
Healthcare

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Learn more
“Oaklins’ efforts enabled us to join Banook and significantly enhance our impact on respiratory drug development. Together with an outstanding transaction team, we were able to efficiently integrate into the Banook platform, backed by Motion Equity Partners.”

Jan De Backer

CEO, Fluidda NV

Read more
Example: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=AT&includes=featured_images,tags&language=de-AT&limit=3&tags=healthcare 
Ours: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=MA&includes=featured_images,tags&language=en&limit=1&tags=healthcare

New chapters, global ambitions: mid-market M&A in Q4

QUARTERLY M&A ACTIVITY: In Q4 2025, Oaklins' clients completed 93 transactions across sectors and regions, highlighting how business leaders are using M&A to drive growth, succession and strategic change.

Learn more

Talk to our local advisor

Ali El Alaoui Faris

Director
Casablanca, Morocco
Oaklins Morocco

Meet our global industry specialists

Antoine Lemaire

Partner
Paris, France
Oaklins France

Stuart Goodman

Partner
London, United Kingdom
Oaklins S&W

Michael Jewell

Partner
London, United Kingdom
Oaklins Cavendish